BAX and nasopharyngeal carcinoma: In Cox univariate regression analysis (Table 3), a 3.5-fold lower risk of recurrence was predicted for NPC patients bearing tumors with negative BAX mRNA expression status (hazard ratio [HR] = 0.28, 95% confidence interval [95% CI] = 0.13-0.62, P = 0.001).